Gary H. Gibbons, M.D.
A sickle cell anemia study has found that the drug hydroxyurea is as effective as blood transfusions in children to reduce blood flow velocities in the brain, which is a key risk factor for stroke. The findings appear in The Lancet and were presented at the annual meeting of the American Society of Hematology.
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults
Tener como objetivo un valor más bajo para la presión arterial reduce en gran medida las complicaciones cardiovasculares y la muerte en los adultos mayores
Dr. Gary H. Gibbons, director of the NHLBI, and Dr. George Mensah, director of NHLBI’s Center for Translational Research and Implementation Science, co-authored a study published in the Journal of the American Heart Association. The study examined the factors existing at the state level that may influence cardiovascular health outcomes.
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases.
The buildup of soft plaque in arteries that nourish the heart is more common and extensive in HIV-infected men than HIV-uninfected men, independent of established cardiovascular disease risk factors, according to a new study by National Institutes of Health grantees. The findings suggest that HIV-infected men are at greater risk for a heart attack than their HIV-uninfected peers, the researchers write in Annals of Internal Medicine.
This question and answer piece (starting on page 14) features NHLBI director Gary H. Gibbons discussing the intersection between research in cardiovascular disease and kidney disease.
Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in achieving stable anticoagulation than using only clinical information, according to a National Institutes of Health-funded clinical trial. In addition, the study found that in African-Americans, anticoagulation control was lower in the genetics-based approach compared to the clinically-based method.
NHLBI Director Dr. Gary Gibbons is interviewed about a genetic mutation that appears linked to low cholesterol levels. Drug companies are now trying to capitaliza on this genetic finding to produce a new cholesterol drug.
The discovery of a rare genetic mutation and of two women with dazzingly low LDL cholesterol levels who carry the mutation has set off one of the greatest medical chases ever. NHLBI Director Dr. Gary H. Gibbons said thousands of people could be candidates for any treatments that result from this work.
Among male twin Vietnam veterans, those with post-traumatic stress disorder (PTSD) were more than twice as likely to have heart disease 13 years after being diagnosed as twin vets without PTSD. The finding suggests that PTSD may be a risk factor for heart disease.
Post-traumatic stress disorder (PTSD) is associated with increased risk of coronary heart disease, according to a recent study led by researchers at Emory’s Rollins School of Public Health and sponsored by the National Institutes of Health.
Chelation therapy, an unproven alternative medicine in the treatment for heart disease, modestly reduced cardiovascular events for adults aged 50 and older who had suffered a prior heart attack, according to new NIH-supported research.
Offered the top job at the NHLBI last year, Gary Gibbons '78 was attracted by the chance to steer an agency with a $3 billion budget for research on heart, lung, and blood disorders. But that wasn’t all. Gibbons, a cardiologist and scientist, also saw the position as an opportunity to address what he calls an "egregious" problem: a dearth of African-American scientists in biomedical research.
Preliminary results from the vitamin component of the Trial to Assess Chelation Therapy (TACT) were released today during the American College of Cardiology’s 2013 Scientific Sessions. The study found that overall heart attack patients given a combination of high-dose oral vitamins and minerals did not exhibit a significant reduction in recurrent cardiac events over those who did not receive the high-dose vitamins and minerals. However, patients who received both high dose vitamins and active chelation compared to the placebo of both appeared to have some additional benefit.
“The results are really, very striking,” said Dr. Yves Rosenberg, project officer for the study and chief of the Atherothrombosis and Coronary Artery Disease Branch at NHLBI. “They showed a clear advantage of surgery for the group of patients we studied. The advantage was clear across the board.”
The 26th annual NIH Research Festival, held Oct. 9-12, was a moveable feast. The plenary session opened with 3 “big vision” talks. NHLBI Director Dr. Gary Gibbons spoke on a systems approach to health inequities. Dr. Jennifer Lippincott-Schwartz of NICHD addressed advances in technology and imaging, and NIAID’s Dr. Ron Germain took the audience on a journey through the immune system.
The National Heart, Lung, and Blood Institute (NHLBI) congratulates the principal investigators and scientific team carrying out the Trial to Assess Chelation Therapy (TACT).
Between 2002 and 2007, use of chelation therapy grew by nearly 68 percent to 111,000 people -- despite there being no evidence as to its safety or efficacy. Given that so many people are trying chelation therapy, it was imperative that a large-scale and very rigorous study be undertaken. The NHLBI is proud to have helped fund such a project.
Diabetic patients with seriously diseased heart arteries are significantly more likely to survive or avoid future attacks by having them treated with bypass surgery than with artery-opening devices called stents, according to a major new study funded by the National Heart, Lung, and Blood Institute.
Results from the NHLBI-funded Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial showed that bypass surgery was superior to PCI, a non-surgical procedure, in treating patients with diabetes and advanced coronary artery disease.
Bypass surgery is a better treatment choice than stenting for diabetics with multivessel coronary artery disease, according to recent results from the NHLBI-funded FREEDOM trial.
An international team of researchers led by Valentin Fuster, M.D., Ph.D., Director of Mount Sinai Heart, has found in the first long-term study of its kind that individuals who have diabetes and advanced coronary artery disease (CAD) live longer and are less likely to suffer a non-fatal heart attack when treated with bypass surgery instead of angioplasty.
The 2012 Nobel Prize in chemistry has been awarded to National Institutes of Health grantees Robert J. Lefkowitz, M.D., of the Howard Hughes Medical Institute and Duke University Medical Center, Durham, N.C.; and Brian K. Kobilka, M.D., of the Stanford University School of Medicine, Stanford, Calif., for studies of protein receptors that let body cells sense and respond to outside signals.
The Royal Swedish Academy of Sciences said the researchers had made groundbreaking discoveries on an important family of receptors known as G-protein-coupled receptors.
Dr. Neal Young, chief of NHLBI's Hematology Branch, received the Sammie in the Science and Environment category.
On 13 August, cardiologist Gary Gibbons became director of the $3 billion National Heart, Lung, and Blood Institute (NHLBI). Gibbons, who turns 56 next week, comes to the third largest National Institutes of Health (NIH) component from Morehouse School of Medicine in Atlanta, where he founded a research center that studied cardiovascular disease in minorities. He previously was a faculty member at Stanford University and Harvard Medical School.
"This is testing a whole new paradigm, a whole new approach, towards treating atherosclerosis," because anti-inflammatory drugs are not now a therapy of choice, says Michael Lauer, director of the Division of Cardiovascular Sciences at NHLBI.
Dr. Gary H. Gibbons discusses his new role as NHLBI director and his experience as a Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program Scholar.
In this Wall Street Journal article Gary H. Gibbons, M.D., director of the NIH's National Heart, Lung, and Blood Institute (NHLBI), and NHLBI grantee Paul Ridker, M.D., director of the center for cardiovascular-disease prevention at Brigham and Women's Hospital in Boston, discuss the launch of the NHLBI-supported cardiovascular inflammation reduction trial (CIRT) that will test if treating inflammation can cut the risk of a heart attack or stroke in high-risk individuals.
The new NHLBI-funded Cardiovascular Inflammation Reduction Trial (CIRT) and the Novartis-funded CANTOS study will both test the theory that inflammation plays a significant role in the underlying biology that makes heart disease the number one cause of death and stroke the number four cause of death in the United States.
In this video, 1994 Pew Biomedical Scholar Gary H. Gibbons, M.D., director of the NIH's National Heart, Lung, and Blood Institute, and 2012 Pew Biomedical Scholar Kathryn E. Wellen, Ph.D., a specialist in cancer metabolism and epigenetics from the University of Pennsylvania, discuss the impact that being a Pew Biomedical Scholar has had on their lives and careers.